Latest Regulation News

DataWorks Group has reported a robust turnaround with a $1.1 million positive operating cash flow in Q2 FY26, underpinned by major government contracts and validated social impact from its BetStop™ platform.

OzAurum Resources has reported promising assay results from its James Stage 1 open pit drilling at Mulgabbie North, confirming consistent shallow high-grade gold mineralisation and supporting a near-term, low-cost heap leach development strategy.

Entropy Neurodynamics reports compelling Phase 2a results showing oral psilocybin dramatically reduces binge eating episodes and related psychiatric symptoms, supporting advancement of its lead IV psilocin candidate.

Brazilian Critical Minerals has successfully demonstrated a 200-fold upgrade in rare earth element concentration using Rare Earth Technologies’ proprietary process, producing high-purity oxides at its Ema project.

Skylark Minerals Limited has applied for ASX quotation of 37.98 million fully paid ordinary shares from a previously approved placement, signalling a key step in its capital expansion strategy.

Aristocrat Leisure has extended its on-market share buy-back program by an additional A$750 million, doubling the total capacity to A$1.5 billion as part of its ongoing capital management strategy.

Eastern Metals Limited will have its trading suspension lifted on 9 January 2026, marking its return to the ASX after meeting key listing requirements.

Elsight Limited has secured a US$460,000 purchase order from a U.S. public safety customer, marking a significant commercial milestone amid accelerating FAA regulations for drone operations beyond visual line of sight.

Estrella Resources has gained regulatory approval to extract a 30,000-tonne bulk sample of high-grade manganese from its Ira Miri project, marking a pioneering step for Timor-Leste’s mining sector under its modern Mining Code.

Mount Hope Mining Limited has explained the late lodgement of director interest disclosures as an administrative oversight, responding to ASX concerns over potential compliance breaches.

BlinkLab Limited has secured independent scientific validation for its smartphone-based autism diagnostic technology through publication in the prestigious journal Autism Research, marking a significant milestone ahead of its FDA regulatory trial.

Island Pharmaceuticals reports ongoing FDA review of its antiviral Galidesivir, with no adverse feedback received as the regulator takes extra time to finalise guidance.